-
Uncategorized3 weeks ago
How To Shine As Biotech Comes Back From the Brink
Biotech has been pulling off some remarkable science of late, while M&A and IPOs return to bolster the sector. But that doesn’t mean the industry is...
-
Uncategorized3 weeks agoBio-IT World Celebrates 25 Years with Opening Plenary on Rare Disease Challenges and Opportunities
BOSTON — Thomas Bartlett’s life changed in 2019 when he was diagnosed with late-onset myasthenia gravis (MG). The 15-year veteran of the Bio-IT World Conference and...
-
Uncategorized3 weeks ago
AI Model Offers Map of How Genes Work Together in Different Cellular Contexts
AI Model Offers Map of How Genes Work Together in Different Cellular Contexts
-
Uncategorized3 weeks agoGuarding biotech from China and big bets in longevity
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT’s Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They...
-
Uncategorized3 weeks ago
How a group of biotechs ran a covert campaign to push out the FDA commissioner
Biohaven CEO Vlad Coric finally had the attention of the FDA, and most importantly, Commissioner Marty Makary. In late April, after the company’s spinocerebellar ataxia drug...
-
Uncategorized3 weeks ago
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
Kissei Pharmaceutical is reversing a recommendation related to Amgen-shared Tavneos that it made just a few days ago, now saying the rare disease drug can be...
-
Uncategorized3 weeks ago
Chutes & Ladders—Former FDA leader takes new biotech Turn
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory...
-
Uncategorized3 weeks agoSTAT+: RFK Jr.’s screen time warning
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
Uncategorized3 weeks agoRA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
-
Uncategorized3 weeks ago
China’s drugmakers to take the stage at #ASCO26
It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical Oncology annual meeting this year....
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
